Docetaxel enhance the response to neodjuvant chemotherapy in stage II and III breast cancer (2008)
Source: European Journal of Surgical Oncology. Conference titles: Congress of the European Society of Surgical Oncology (EJSO). Unidade: FMRP
Assunto: NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA)
ABNT
TIEZZI, Daniel Guimarães et al. Docetaxel enhance the response to neodjuvant chemotherapy in stage II and III breast cancer. European Journal of Surgical Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 07 nov. 2024. , 2008APA
Tiezzi, D. G., Andrade, J. M., Machetti, A., Martins Neto, J. C. S., Marana, H. R. C., Cagnan, W. S., et al. (2008). Docetaxel enhance the response to neodjuvant chemotherapy in stage II and III breast cancer. European Journal of Surgical Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Tiezzi DG, Andrade JM, Machetti A, Martins Neto JCS, Marana HRC, Cagnan WS, Zola FE, Peria FM. Docetaxel enhance the response to neodjuvant chemotherapy in stage II and III breast cancer. European Journal of Surgical Oncology. 2008 ; 34( 9): 1063.[citado 2024 nov. 07 ]Vancouver
Tiezzi DG, Andrade JM, Machetti A, Martins Neto JCS, Marana HRC, Cagnan WS, Zola FE, Peria FM. Docetaxel enhance the response to neodjuvant chemotherapy in stage II and III breast cancer. European Journal of Surgical Oncology. 2008 ; 34( 9): 1063.[citado 2024 nov. 07 ]